Skip to main content
NCBI home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1988 Feb;47(2):96–104. doi: 10.1136/ard.47.2.96

Effects of altering dietary essential fatty acids on requirements for non-steroidal anti-inflammatory drugs in patients with rheumatoid arthritis: a double blind placebo controlled study.

J J Belch 1, D Ansell 1, R Madhok 1, A O'Dowd 1, R D Sturrock 1
PMCID: PMC1003460  PMID: 2833184

Abstract

In rheumatoid arthritis (RA) benefit from non-steroidal anti-inflammatory drugs (NSAIDs) is mediated through inhibition of the cyclo-oxygenase enzyme, thereby decreasing production of the 2 series prostaglandins (PGs). The lipoxygenase enzyme is intact, however, allowing leucotriene (LT) production, e.g., LTB4 (an inflammatory mediator). Treatment with evening primrose oil (EPO) which contains gamma-linolenic acid (GLA) leads to production of the 1 series PGs, e.g., PGE1, which has less inflammatory effects. Also LT production is inhibited. Eicosapentaenoic acid (EPA, fish oil) treatment provides a substrate for PGs and LTs, which are also less inflammatory. In this study 16 patients with RA were given 540 mg GLA/day (EPO), 15 patients 240 mg EPA and 450 mg GLA/day (EPO/fish oil), and 18 patients an inert oil (placebo). The aim of this study was to determine if EPO or EPO/fish oil could replace NSAID treatment in RA. The initial 12 month treatment period was followed by three months of placebo for all groups. Results at 12 months showed a significant subjective improvement for EPO and EPO/fish oil compared with placebo. In addition, by 12 months the patients receiving EPO and EPO/fish oil had significantly reduced their NSAIDs. After 3 months of placebo those receiving active treatment had relapsed. Despite the decrease in NSAIDs, measures of disease activity did not worsen. It is suggested that EPO and EPO/fish oil produce a subjective improvement and allow some patients to reduce or stop treatment with NSAIDs. There is, however, no evidence that they act as disease modifying agents.

Full text

PDF
96

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Elliott G. R., Adolfs M. J., Van Batenburg M., Bonta I. L. Linoleic and dihomo-gamma-linolenic acids modulate granuloma growth and granuloma macrophage eicosanoid release. Eur J Pharmacol. 1986 May 27;124(3):325–329. doi: 10.1016/0014-2999(86)90234-7. [DOI] [PubMed] [Google Scholar]
  2. Epstein M., Lifschitz M., Rappaport K. Augmentation of prostaglandin production by linoleic acid in man. Clin Sci (Lond) 1982 Dec;63(6):565–571. doi: 10.1042/cs0630565. [DOI] [PubMed] [Google Scholar]
  3. Fisher J. M., Donegan D. R., Leon H., Willis A. L. Effects of prostaglandins and their precursors in some tests of hemostatic function. Prog Lipid Res. 1981;20:799–805. doi: 10.1016/0163-7827(81)90150-8. [DOI] [PubMed] [Google Scholar]
  4. Jäntti J., Isomäki H., Laitinen O., Nikkari T., Seppälä E., Vapaatalo H. Linoleic acid treatment in inflammatory arthritis. Int J Clin Pharmacol Ther Toxicol. 1985 Feb;23(2):89–91. [PubMed] [Google Scholar]
  5. Kremer J. M., Bigauoette J., Michalek A. V., Timchalk M. A., Lininger L., Rynes R. I., Huyck C., Zieminski J., Bartholomew L. E. Effects of manipulation of dietary fatty acids on clinical manifestations of rheumatoid arthritis. Lancet. 1985 Jan 26;1(8422):184–187. doi: 10.1016/s0140-6736(85)92024-0. [DOI] [PubMed] [Google Scholar]
  6. Mertin J., Stackpoole A. Anti-PGE antibodies inhibit in vivo development of cell-mediated immunity. Nature. 1981 Dec 3;294(5840):456–458. doi: 10.1038/294456a0. [DOI] [PubMed] [Google Scholar]
  7. Prescott S. M. The effect of eicosapentaenoic acid on leukotriene B production by human neutrophils. J Biol Chem. 1984 Jun 25;259(12):7615–7621. [PubMed] [Google Scholar]
  8. Prickett J. D., Robinson D. R., Steinberg A. D. Effects of dietary enrichment with eicosapentaenoic acid upon autoimmune nephritis in female NZB X NZW/F1 mice. Arthritis Rheum. 1983 Feb;26(2):133–139. doi: 10.1002/art.1780260203. [DOI] [PubMed] [Google Scholar]
  9. Ritchie D. M., Boyle J. A., McInnes J. M., Jasani M. K., Dalakos T. G., Grieveson P., Buchanan W. W. Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. Q J Med. 1968 Jul;37(147):393–406. [PubMed] [Google Scholar]
  10. Szczeklik A., Gryglewski R. J., Domagala B., Dworski R., Basista M. Dietary supplementation with vitamin E in hyperlipoproteinemias: effects on plasma lipid peroxides, antioxidant activity, prostacyclin generation and platelet aggregability. Thromb Haemost. 1985 Aug 30;54(2):425–430. [PubMed] [Google Scholar]
  11. Voorhees J. J. Leukotrienes and other lipoxygenase products in the pathogenesis and therapy of psoriasis and other dermatoses. Arch Dermatol. 1983 Jul;119(7):541–547. [PubMed] [Google Scholar]
  12. Wright S., Burton J. L. Oral evening-primrose-seed oil improves atopic eczema. Lancet. 1982 Nov 20;2(8308):1120–1122. doi: 10.1016/s0140-6736(82)92784-2. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES